circ_0008043通过miR-198/SLC2A1轴促进肝癌糖酵解及肝癌发展

doi:10.11904/j.issn.1002-3070.2024.06.007

Abstract

Abstract: Objective The aim of this study was to investigate the mechanism of circ_0008043 regulating glycolysis of hepatocellular carcinoma(HCC)cells. Methods The expression of circ_0008043,miR-198 and SLC2A1 in clinical samples and HCC cell lines was detected by qPCR,and the targeted binding of circ_0008043 to miR-198 and miR-198 to SLC2A1 was verified by dual luciferase reporting assay.HCC cells were transfected with sh-circ_0008043/sh-NC,miR-198 inhibitor/miR-198 inhibitor-NC,miR-198 mimic/mimic NC,or pcDNA3.1-SLC2A1/pcDNA3.1-NC to detected the effects of circ_0008043,miR-198 and SLC2A1 on the glycolysis of HCC cells.The effect of circ_0008043 on tumor growth in HCC was verified by HCC cell xenografts through a nude mouse model. Results circ_0008043 was highly expressed in both HCC tissues and cell lines(P＜0.01).Silencing circ_0008043 could inhibit the glycolysis of HCC cells.The expression of miR-198 was decreased in HCC tissues and cell lines(P＜0.001)and negatively correlated with the expression of circ_0008043(r=-0.550,P＜0.001).The inhibition of glycolysis caused by silencing circ_0008043 was partially restored by inhibiting miR-198 expression.SLC2A1 was highly expressed in HCC tissues and cell lines(P＜0.001),and overexpression of SLC2A1 reversed the inhibitory effect of miR-198 on glycolysis in HCC cells.The nude mouse experiment showed that silencing circ_0008043 could inhibit the growth of HCC cell xenografts(P＜0.001). Conclusion circ_0008043 promotes HCC cell glycolysis and growth through the miR-198/SLC2A1 axis.

Key words: Hepatocellular carcinoma, Glycolysis, circ_0008043, miR-198, SLC2A1

CLC Number:

R735.7

ZHANG Kangjun, FANG Taishi, CEN Fulan, YAN Xu, CHEN Qijun, MA Nan. circ_0008043 promotes glycolysis of hepatocellular carcinoma and the development of hepatocellular carcinoma through miR-198/SLC2A1 axis[J]. Journal of Practical Oncology, 2024, 38(6): 388-401.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.06.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I6/388

References

1 Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet 2018,391(10127):1301-1314.
2 中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南(2022年版)[J].肿瘤综合治疗电子杂志,2022,8(2):16-53.
3 Chaichian S,Shafabakhsh R,Mirhashemi SM,et al.A novel biomarker for cervical cancer[J].J Cell Physiol,2020,235(2):718-724.
4 Liu X,Zhang Y,Zhou S,et al.Circular RNA:an emerging frontier in RNA therapeutic targets,RNA therapeutics,and mRNA vaccines[J].J Control Release,2022,348:84-94.
5 Liu Z,Zhou Y,Liang G,et al.Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p[J].Cell Death Dis,2019,10(2):55.
6 Wang X,Li J,Bian X,et al.CircURI1 interacts with hnRNPM to inhibit metastasis by modulating alternative splicing in gastric cancer[J].Proc Natl Acad Sci U S A,2021,118(33):e2012881118.
7 Xu J,Ji L,Liang Y,et al.CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1[J].Signal Transduct Tar,2020,5(1):298.
8 Kristensen LS,Andersen MS,Stagsted LVW,et al.The biogenesis,biology and characterization of circular RNAs[J].Nat Rev Genet,2019,20(11):675-691.
9 Du A,Li S,Zhou Y,et al.M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma[J].Mol Cancer,2022,21(1):109.
10 王煜宁,王亚静,张颐.HIF-1α在肿瘤细胞糖酵解中的作用[J].中国医科大学学报,2023,52(7):644-648.
11 Xiao Y,Yang K,Liu P,et al.Deoxyearibonuclease 1-like 3 inhibits hepatocellular carcinoma progression by inducing apoptosis and reprogramming glucose metabolism[J].Int J Biol Sci,2022,18(1):82-95.
12 DeWaal D,Nogueira V,Terry AR,et al.Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J].Nat Commun,2018,9(1):446.
13 Lin J,Wang X,Zhai S,et al.Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1[J].J Hematol Oncol,2022,15(1):128.
14 Wang X,Zhang H,Yang H,et al.Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer[J].Mol Oncol,2020,14(3):539-555.
15 Li Q,Pan X,Zhu D,et al.Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p/PKM2 axis under hypoxic stress[J].Hepatology 2019,70(4):1298-1316.
16 Zhang K,Fang T,Zhao D,et al.Circular RNA Circ_0008043 promotes the proliferation and metastasis of hepatocellular carcinoma cells by regulating the microRNA(miR)-326/RAB21 axis[J].Bioengineered,2022,13(3):6600-6614.
17 Tomayko MM,Reynolds CP.Determination of subcutaneous tumor size in athymic(nude)mice[J].Cancer Chemoth Pharm,1989,24(3):148-154.
18 Wu P,Mo Y,Peng M,et al.Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA[J].Mol Cancer,2020,19(1):22.
19 Wesselhoeft RA,Kowalski PS,Anderson DG.Engineering circular RNA for potent and stable translation in eukaryotic cells[J].Nat Commun,2018,9(1):2629.
20 Hansen TB,Jensen TI,Clausen BH,et al.Natural RNA circles function as efficient microRNA sponges[J].Nature,2013,495(7441):384-388.
21 Huang G,Liang M,Liu H,et al.CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/beta-catenin pathway[J].Cell Death Dis,2020,11(12):1065.
22 Tan S,Li R,Ding K,et al.miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway[J].Febs Lett,2011,585(14):2229.
23 Li M,Chen H,Xia L,et al.Circular RNA circSP3 promotes hepatocellular carcinoma growth by sponging microRNA-198 and upregulating cyclin-dependent kinase 4[J].Aging(Albany NY),2021,13(14):18586.
24 Ganapathy-Kanniappan S,Geschwind JF.Tumor glycolysis as a target for cancer therapy:progress and prospects[J].Mol Cancer,2013,12:152.
25 Mo Y,Wang Y,Zhang S,et al.Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2[J].Mol Cancer,2021,20(1):112.

[1]	GUAN Yongyu, NIE Hao, ZHANG Chong. Research progress of hepatocellular carcinoma mouse models [J]. Journal of Practical Oncology, 2024, 38(5): 342-348.
[2]	LIAO Jun, LI Chunfeng, XUE Yingwei, ZU Hongliang. Research progress of lactate dehydrogenase in the diagnosis and treatment of gastric cancer [J]. Journal of Practical Oncology, 2024, 38(3): 200-206.
[3]	WANG Wenbo, BAI Haixin, ZHANG Tan, NIU Li. Propofol inhibits glycolysis and tumor progression in lung cancer through GLUT4 [J]. Journal of Practical Oncology, 2024, 38(2): 104-111.
[4]	WU Dongyang, CAI Qingshan, LIU Dong, ZUO Ganggang, LI Shudong, LIU Liyou, ZHENG Jianxing. The effects and mechanism of long non-coding RNA CASC15 on proliferation,invasion and migration of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2024, 38(1): 18-29.
[5]	PANG Wu, CHEN Lijiang, ZHU Yu, WU Yakun, ZHANG Wei. The expression of serum miRNA-24 and miRNA-509 in patients with hepatocellular carcinoma and their correlation with prognosis [J]. Journal of Practical Oncology, 2023, 37(5): 411-415.
[6]	CUI Yongkang, YU Chengping, XU Haozhi, MA Xinyu, MA Yong, LI Linqiang. Effects of nutritional risk index in predicting postoperative complications and prognosis of patients with resectable hepatocellular carcinoma [J]. Journal of Practical Oncology, 2023, 37(3): 243-251.
[7]	YIN Dingwei, JING Jie. Research progress on the role of Gut microbiota in hepatocellular carcinoma and its therapeutic application [J]. Journal of Practical Oncology, 2023, 37(3): 281-286.
[8]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[9]	LIU Jia, YANG Daokun, WANG Yanping, CHEN Baoxin, WANG Xinwei, SHEN Jiao. Research status of biomarkers related to the efficacy of PD-1 inhibitors in the treatment of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(4): 374-380.
[10]	LIU Jiaming, CUI Yifeng, LU Zhaoyang. Aqueous Huaier extract inhibits the proliferation and metastasis of hepatocellular carcinoma by regulating the Akt signaling pathway through mitochondrial transcription factor A [J]. Journal of Practical Oncology, 2022, 36(3): 203-207.
[11]	PANG Chunhua, LI Fanrong, TANG Rubing, QIN Lei, ZHAO Xinhua, TANG Juan, YOU Xuemei. Association between preoperative fatigue status and postoperative quality of life in patients with advanced hepatocellular carcinoma:a prospective cohort study [J]. Journal of Practical Oncology, 2022, 36(2): 127-132.
[12]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[13]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[14]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[15]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.

circ_0008043 promotes glycolysis of hepatocellular carcinoma and the development of hepatocellular carcinoma through miR-198/SLC2A1 axis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments